JP2019531346A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531346A5
JP2019531346A5 JP2019536463A JP2019536463A JP2019531346A5 JP 2019531346 A5 JP2019531346 A5 JP 2019531346A5 JP 2019536463 A JP2019536463 A JP 2019536463A JP 2019536463 A JP2019536463 A JP 2019536463A JP 2019531346 A5 JP2019531346 A5 JP 2019531346A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
group
substituted
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019536463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531346A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/051410 external-priority patent/WO2018053036A1/en
Publication of JP2019531346A publication Critical patent/JP2019531346A/ja
Publication of JP2019531346A5 publication Critical patent/JP2019531346A5/ja
Priority to JP2022148311A priority Critical patent/JP7656574B2/ja
Pending legal-status Critical Current

Links

JP2019536463A 2016-09-16 2017-09-13 甲状腺関連副作用を低下させる方法 Pending JP2019531346A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022148311A JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662396015P 2016-09-16 2016-09-16
US201662396025P 2016-09-16 2016-09-16
US62/396,025 2016-09-16
US62/396,015 2016-09-16
PCT/US2017/051410 WO2018053036A1 (en) 2016-09-16 2017-09-13 Method of reducing thyroid-associated side effects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022148311A Division JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Publications (2)

Publication Number Publication Date
JP2019531346A JP2019531346A (ja) 2019-10-31
JP2019531346A5 true JP2019531346A5 (enExample) 2020-10-22

Family

ID=61619247

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019536463A Pending JP2019531346A (ja) 2016-09-16 2017-09-13 甲状腺関連副作用を低下させる方法
JP2022148311A Active JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022148311A Active JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Country Status (9)

Country Link
US (1) US20190255080A1 (enExample)
EP (1) EP3512523A4 (enExample)
JP (2) JP2019531346A (enExample)
KR (2) KR20240074912A (enExample)
CN (2) CN121695155A (enExample)
AU (1) AU2017327383B2 (enExample)
CA (1) CA3037146A1 (enExample)
MX (2) MX2019003032A (enExample)
WO (1) WO2018053036A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542301A (ja) 2005-05-26 2008-11-27 メタバシス・セラピューティクス・インコーポレイテッド 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤
EP3541395A4 (en) 2016-11-21 2020-07-01 Viking Therapeutics, Inc. GLYCOGENOSIS TREATMENT METHODS
EP3634426A4 (en) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. COMPOSITIONS FOR TREATMENT OF FIBROSE
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
BR112021021923A2 (pt) * 2019-05-08 2022-02-22 Novartis Ag Anticorpos anti-cd40 para uso no tratamento de dm1 e insulite
RU2728261C2 (ru) * 2019-05-22 2020-07-28 Ирина Алексеевна Курникова Способ дифференциальной диагностики йоддефицитного и йодиндуцированного нарушения функции щитовидной железы у лиц, проживающих в регионах с йодным дефицитом
CN112457346B (zh) * 2019-08-19 2022-09-06 和博医药有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途
US12378268B2 (en) 2019-08-19 2025-08-05 Hepagene Therapeutics (HK) Limited Heterocyclic THR-β receptor agonist compound and preparation method and use therefor
JP7670687B2 (ja) * 2020-02-24 2025-04-30 へパジーン セラピューティクス (エイチケイ) リミテッド 複素環式THR-β受容体アゴニスト化合物ならびにその調製方法および使用
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
MXPA04012497A (es) * 2002-07-04 2005-07-14 Zealand Pharma As Glp-1 y metodos para tratar la diabetes.
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
JP2008542301A (ja) * 2005-05-26 2008-11-27 メタバシス・セラピューティクス・インコーポレイテッド 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤
WO2009089093A1 (en) * 2008-01-04 2009-07-16 Quatrx Pharmaceuticals Company Thyroid hormone receptor agonists
CA2732686C (en) * 2008-12-22 2017-10-03 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
US20170319604A1 (en) * 2016-04-22 2017-11-09 Metabasis Therapeutics, Inc. Thyroid hormone receptor agonist and use thereof

Similar Documents

Publication Publication Date Title
JP2019531346A5 (enExample)
RU2020123241A (ru) Полициклические соединения в качестве аллостерических ингибиторов shp2
JP2016509047A5 (enExample)
JP2020505376A5 (enExample)
JP2020506178A5 (enExample)
JP2020515610A5 (enExample)
JP2020536881A5 (enExample)
JP2016505586A5 (enExample)
JP2019094345A5 (enExample)
JP2015532295A5 (enExample)
JP2020500866A5 (enExample)
JP2017505314A5 (enExample)
JP2009526761A5 (enExample)
JP2016517417A5 (enExample)
JP2007505933A5 (enExample)
JP2017526726A5 (enExample)
JP2013512903A5 (enExample)
JP2017518959A5 (enExample)
JP2013542996A5 (enExample)
JP2010524932A5 (enExample)
JP2019518059A5 (enExample)
JP2019510787A5 (enExample)
WO2009009501A4 (en) Non-basic melanin concentrating hormone receptor-1 antagonists and methods
JP2014514290A5 (enExample)
JP2012532137A5 (enExample)